Allogene Therapeutics (ALLO) FCF conversion US GAAP (year values)
FY2021 FY2022 FY2023 FY2024 FY2025   LTM ? CAGR 5 years ?
FCF conversion, % 121.5% 70.3% 76.4% 82.6% 84.3%   65.2%  
Changes by years, y/y, % +46pp -51pp +6pp +6pp +2pp     +2.1%
Compare with other companies

Allogene Therapeutics. FCF conversion, %

Allogene Therapeutics. FCF conversion, changes, pp

Allogene Therapeutics (ALLO) FCF conversion US GAAP (quarter values)
FY2025Q2 FY2025Q3 FY2025Q4 FY2026Q1 FY2026Q2   LTM ?
FCF conversion, % 82.1% 78.9% 77.9% 32.8% 81.0%   65.2%
Changes by years, y/y, % -19pp +8pp +12pp -61pp -1pp    
Changes by quarters, q/q, % -12pp -3pp -1pp -45pp +48pp    

Allogene Therapeutics. FCF conversion, %

Allogene Therapeutics. FCF conversion, changes, pp

Allogene Therapeutics. FCF conversion, changes, pp


Have an idea?
Blogs All blogs wire
Most useful
Most commented
NEWS
Trade Signals
Answers to questions
Books reviews
Corporate blogs
Forums All forums wire
Common
Stocks
Algotrading
Options
Cryptocurrencies
Forex
Brokers rating
Stocks Heat Map
Quotes
Fundamental analysis
Financials
Dividends
My portfolio
All companies
Stocks Calendar
Smartlab Smartlab Values
SiteMap
Ads
Contacts

Rules
Help
Feedback
Moscow Exchange is the source and the owner of marketdata. The users haven't right of further distribution or presentation of any data without written permission of Moscow Exchange, haven't right to create modified information for further public distribution to third parties.